Printer Friendly

INTERNATIONAL MUREX TECHNOLOGIES CORPORATION SIGNS DEVELOPMENT AND LICENSE AGREEMENT FOR DNA PROBE TECHNOLOGY

 NORCROSS, Ga., April 29 /PRNewswire/ -- International Murex Technologies Corporation (AMEX: MXX; TSE) (IMTC) announced today that it has signed a Development and License Agreement with Digene Diagnostics, Inc. (Digene) of Silver Spring, Md., for DNA probe product development in defined areas of infectious diseases, including retroviruses, hepatitis and mycobacteria.
 IMTC and Digene will both market these products through their distribution networks to clinical laboratories and hospitals worldwide.
 IMTC began to market Digene's HBV (Hepatitis B) and HPV (Human Papilloma Virus) DNA Probe tests in Europe and other regions in 1992 and early 1993 respectively. These products broke new ground because their sensitivity (lack of false negatives) was comparable to radio isotopic probes, yet the process was simpler and quicker (approximately) four hours vs. three days) than other available products. Sales of these products grew steadily in 1992 and through the first quarter of 1993.
 "We believe that Digene's high quality DNA probe products will become increasingly important in the diagnosis of infectious diseases, with the potential to replace current testing methods. We are entering into this new agreement to strengthen IMTC's commitment to this market and to strengthen our relationship with Digene," stated C. Robert Cusick, president and chief executive officer of IMTC. "IMTC anticipates the next product based upon the IMTC/Digene agreement will be launched within 12 months."
 "The IMTC/Digene agreement will help accelerate the development of new products based on Digene's Hybrid Capture(TM) technology. The new tests which are already under development address significant clinical and market needs," stated Evan Jones, president and chief executive officer of Digene. "IMTC has proven to be an effective marketing partner for Digene's first two Hybrid Capture assays, and the rapid addition of new tests will benefit both companies." Digene is a leader in the market for genetic probe diagnostic testing. The company's initial focus is in the area of infectious disease testing.
 IMTC is a medical diagnostic products company dedicated to the research, manufacture and marketing of products for the detection, monitoring and screening of infectious diseases and other medical conditions, and for blood grouping. IMTC has FDA approved manufacturing facilities in Norcross and Dartmouth, Nova Scotia. Additionally, the company's European subsidiary, Murex Diagnostics (formerly Wellcome Diagnostics) of Dartford, England, was one of the first U.K.-based in vitro diagnostic companies certified under the ISO 9001 regulations covering the design, manufacture and distribution of medical diagnostic products. IMTC employs approximately 670 people worldwide. The company manufactures and markets more than 650 products including a range of mass screening diagnostic tests and its unique rapid (10 minute) SUDS(R) test for the detection of antibodies to HIV-1 and HIV-2.
 For more information contact C. Robert Cusick, president and chief executive officer or Marcia M. Young, director of Corporate Communications at 800-322-1332, or 404-662-0660.
 -0- 4/29/93
 /CONTACT: Marcia M. Young, director of Corporate Communications of International Murex Technologies Corporation, 800-322-1332/
 (MXX)


CO: International Murex Technologies Corporation ST: Georgia IN: MTC SU: LIC

BR-RA -- AT002 -- 2519 04/29/93 10:02 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 29, 1993
Words:504
Previous Article:APPLE PRESS CONFERENCE AT DB/EXPO; TO INTRODUCE DAL PRODUCTS AND SUPPORT FOR ODBC
Next Article:CONTEL CELLULAR REPORTS FIRST QUARTER RESULTS FOR 1993
Topics:


Related Articles
INTERNATIONAL MUREX TECHNOLOGIES REPORTS SECOND QUARTER 1994 RESULTS; GROWING REVENUES AND PROFITS
INTERNATIONAL MUREX TECHNOLOGIES REPORTS THIRD QUARTER 1994 RESULTS STEADY GROWTH IN REVENUES, EPS AND PROFITS
INTERNATIONAL MUREX TECHNOLOGIES CORPORATION SETTLES CLASS ACTION AND CAMPBELL COURT CASES
INTERNATIONAL MUREX TECHNOLOGIES REPORTS SECOND QUARTER 1995 RESULTS
INTERNATIONAL MUREX SIGNS EXCLUSIVE LICENSE WITH BIOSTAR TO MARKET SUPERIOR STREP TESTS TO A $35 MILLION MARKET
Chiron, Ortho Diagnostic Systems and International Murex Reach Worldwide HCV Agreement
International Murex Returns to Profitability; Reports 1996 Third Quarter Income of $.08 Per Share
International Murex Reports 1996 Year End Earnings of $0.11 Per Share
Revolutionary HIV Drug Resistance Test Launched Worldwide By International Murex
Digene Corporation Announces Marketing and Distribution Alliance With Abbott Laboratories.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters